Growth differentiation factor 15 predicts advanced fibrosis in biopsy-proven non-alcoholic fatty liver disease
Growth differentiation factor 15 predicts advanced fibrosis in biopsy-proven non-alcoholic fatty liver disease
复制标题
生长分化因子15预测经活检证实的非酒精性脂肪性肝病的晚期纤维化
DOI：
10.1111/liv.13587
复制
发表时间：
2018-04-01
影响因子：
6.7
通讯作者：
Kim, Won
中科院分区：
文献类型：
--
作者：
Koo, Bo Kyung;Um, Sung Hee;Kim, Won
背景与目的我们探讨了生长分化因子15（GDF 15）是否影响非酒精性脂肪性肝病（NAFLD）的组织学严重程度，与胰岛素抵抗无关。方法在一个经活检证实的NAFLD队列中，我们使用酶联免疫吸附测定法测定了血清GDF 15水平。平均年龄5314岁，男性52.1%，非酒精性脂肪肝（NAFL）72例，非酒精性脂肪性肝炎（NASH）78例，分别占65.3%和44.9%。NASH患者的GDF 15水平显著高于对照组（P=.010）或NAFL患者（P=.001）。与其他受试者相比，晚期纤维化受试者（F3）也显示出更高的GDF 15水平（F0-2; P
Background & AimsWe explored whether growth differentiation factor 15 (GDF15) affects the histological severity of non-alcoholic fatty liver disease (NAFLD) independent of insulin resistance.MethodsIn a biopsy-proven NAFLD cohort, we measured serum GDF15 levels using enzyme-linked immunosorbent assays.ResultsAmong 190 subjects (mean age, 5314years; men, 52.1%), 72 (men, 65.3%) and 78 (men, 44.9%) were diagnosed with biopsy-proven non-alcoholic fatty liver (NAFL) and non-alcoholic steatohepatitis (NASH) respectively. GDF15 levels were significantly higher in NASH patients than in controls (P=.010) or NAFL patients (P=.001). Subjects with advanced fibrosis (F3) also showed higher GDF15 levels compared to the others (F0-2; P